Antidepressants May Thwart Brain Inflammation
the Psychiatry Advisor take:
A selective serotonin reuptake inhibitor (SSRI) may do more than just treat depression. The antidepressant may also have a neuroprotective role by helping to reduce neurotoxic compounds that can destroy brain cells.
Angelos Halaris, PhD, Loyola University Chicago Stritch School of Medicine, and colleagues studied patients who were prescribed escitalopram to see the impact of the SSRI on immune response. Eight percent of patients who completed the trial reported some degree of remission from depressive symptoms.
Recent research has suggested that there is a relationship between depression and an increase in inflammation in the brain. With this in mind, the researchers aimed to find out if an antidepressant could also reverse any harm on the immune system that depression might cause.
The team also took blood samples from the patients to measure the levels of nine chemicals associated with an immune reaction. Eight of them were found to be higher than normal in depressed patients. However, two neurotoxic compounds, 3-hydroxykynurenine and 3-hydroxykynurenine, declined during treatment with escitalopram, the researchers reported in the Journal of Psychiatric Research.
Since the study only involved 20 patients, Halaris is hoping that the results can be replicated, and also tested to see if the neuroprotective effects are seen in other SSRIs.
Depressed patients who took the SSRI escitalopram also saw declines in two neurotoxic compounds associated with inflammation.
New research published in the Journal of Psychiatric Research investigates a potentially neuroprotective role of escitalopram, a common antidepressant drug.
Serotonin, a neurotransmitter derived from tryptophan, plays a myriad of roles in the human body. This chemical, or, to be precise, pathways involving serotonin, have been implicated in depression since the 1960s.
The so-called serotonin theory has been the leading explanation of depression's etiology for many years. This excerpt comes from a landmark paper published in The Lancet in 1969. In other words, the molecular building block of serotonin - tryptophan - is in lower quantities, leading to a decrease in serotonin production. The reduction in serotonin leads to a reduction in mood.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Improving Performance of Everyday Activities Is Critical in Schizophrenia
- Analysis Finds Lithium Maintenance Most Effective as Monotherapy in Bipolar Disorder
- Web-Based Intervention Targets Parental Behaviors That May Affect Adolescent Anxiety, Depression
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Examining Associations Between Diabetes and Effects on Cognition
- Untreated Depression Common in Women of Childbearing Age
- Incidence of Psychiatric Disorders in Rheumatoid Arthritis
- Effect of Antidepressant Class, Dose on Pediatric Anxiety Disorders